Drugs / talfirastide
talfirastide
also known as
Angiotensin 1-7 · TXA-127 · Ang-(1-7) · A(1-7) · 5-ile-angiotensin-(1-7) · Angiotensin fragment 1-7 · Angiotensin peptide (1-7) · Asp-arg-val-tyr-ile-his-pro · +8 more
Trials 31
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 07 trials | ||||||
| Phase 0 | NCT06482853 | Jan 2025 → Mar 2029 expected | hypertensive disorder, obesity disorder | Milton S. Hershey Medical Center | Recruiting | No outcome recorded |
| Phase 0 | NCT05301192 | Dec 2022 → Jun 2024 | — | Milton S. Hershey Medical Center | Terminated | No outcome recorded Stop: Business |
| Phase 0 | NCT03777215 | Sep 2019 → Apr 2026 | obesity disorder | Amy Arnold | Completed | No outcome recorded |
| Phase 0 | NCT03604289 | Apr 2019 → May 2023 | hypertensive disorder, obesity disorder | Amy Arnold | Terminated | No outcome recorded Stop: Business |
| Phase 0 | NCT03240068 | Sep 2017 → Mar 2020 | peripheral arterial disease | Milton S. Hershey Medical Center | Terminated | No outcome recorded Stop: Business |
| Phase 0 | NCT02591173 | Feb 2016 → Jul 2020 | orthostatic hypotension, pure autonomic failure | Vanderbilt University Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT03001271 | Jan 2014 → Feb 2017 | hypertensive disorder | Instituto de Cardiologia do Rio Grande do Sul | Unknown | No outcome recorded |
| Phase 16 trials | ||||||
| Phase 1 | NCT02646475 | Feb 2016 → Dec 2029 expected | hypertensive disorder, metabolic syndrome X, obesity disorder | Vanderbilt University | Recruiting | No outcome recorded |
| Phase 1 | NCT02245230 | Jan 2015 → Dec 2023 | essential hypertension | Vanderbilt University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01362036 | Apr 2011 → Apr 2012 | myelodysplastic syndrome | Tarix Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01300611 | Jan 2011 → Dec 2020 | Hodgkins lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia +2 | Tarix Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT00757250 | Sep 2008 → Dec 2011 | HIV infectious disease | US Biotest, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00471562 | Mar 2007 → Oct 2009 | cancer of unknown primary site | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 1/24 trials · 1 missed | ||||||
| Phase 1/2 | NCT06282965 | May 2024 → Sep 2027 expected | traumatic brain injury | University of Arizona | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05336175 | Apr 2022 → Dec 2023 | advanced heart failure, mild heart failure, moderate heart failure | University of Arizona | Unknown | No outcome recorded |
| Phase 1/2 | NCT04570501 | Feb → Aug 2022 | COVID-19 | Stanford University | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04633772 | Aug 2020 → Nov 2021 | COVID-19, respiratory failure | Erasme University Hospital | Completed | Missed primary |
| Phase 212 trials | ||||||
| Phase 2 | NCT06135103 | Nov 2023 → Dec 2024 | ischemic stroke | Constant Therapeutics LLC | Unknown | No outcome recorded |
| Phase 2 | NCT06013839 | Aug 2023 → Aug 2024 | dilated cardiomyopathy | Constant Therapeutics LLC | Unknown | No outcome recorded |
| Phase 2 | NCT04778059 | Jul 2021 → May 2022 | COVID-19, adult acute respiratory distress syndrome | US Biotest, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04401423 | Feb → Jun 2021 | COVID-19 | Columbia University | Completed | No outcome recorded |
| Phase 2 | NCT03252093 | Jul 2017 → Nov 2022 | cognitive impairment with or without cerebellar ataxia | University of Arizona | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT03159988 | Apr 2016 → Jun 2026 | cognitive disorder, heart failure | University of Arizona | Suspended | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01882387 | Dec 2013 | hematopoietic and lymphoid cell neoplasm | Tarix Pharmaceuticals | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT01882374 | Dec 2013 | hematopoietic and lymphoid system neoplasm | Tarix Pharmaceuticals | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT01554254 | Mar 2012 → Dec 2013 | hematopoietic and lymphoid cell neoplasm, inborn errors of metabolism | Tarix Pharmaceuticals | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01121120 | Jun 2010 → Dec 2020 | Hodgkins lymphoma, non-Hodgkin lymphoma, plasma cell myeloma | Tarix Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01553539 | Oct 2009 → Jan 2013 | bone cancer, chondrosarcoma, clear cell sarcoma of kidney, osteosarcoma +2 | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00771810 | Oct 2008 → Dec 2011 | anemia, lymphopenia, neutropenia, thrombocytopenia | Tarix Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/32 trials · 1 missed | ||||||
| Phase 2/3 | NCT04332666 | Dec 2021 → Dec 2022 | COVID-19, respiratory failure | Erasme University Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT04924660 | Jul 2021 → Oct 2023 | COVID-19 | Sean Collins | Completed | Missed primary |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT01543971 Comparator | Dec 2009 | — | Tarix Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT04605887 Comparator | Jan 2021 → Nov 2023 | COVID-19 | Rambam Health Care Campus | Unknown | No outcome recorded |
| — | NCT04375124 Comparator | Apr → Aug 2020 | COVID-19 | Kanuni Sultan Suleyman Training and Research Hospital | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2017-02-17 | Constant Therapeutics LLC | Regulatory Tarix Orphan Granted Orphan Drug Status for TXA127 as Potential Treatment for Congenital Muscular Dystrophy (MDC1A) constanttherapeutics.com ↗
Tarix Orphan LLC today announced that the U.S. Food and Drug Administration has granted Orphan Drug status to the company’s lead compound, TXA127, for the treatment of laminin-‐deficient congenital muscular dystrophy (LAMA2 MD or MDC1A). |
| 2017-01-18 | Constant Therapeutics LLC | Regulatory Tarix Orphan Receives Rare Pediatric Disease Designation for TXA127 for Recessive Dystrophic Epidermolysis Bullosa (RDEB) constanttherapeutics.com ↗
Tarix Orphan LLC today announced that the U.S. Food and Drug Administration has granted a Rare Pediatric Disease (RPD) designation for the company’s drug candidate TXA127 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. |
| 2015-10-06 | Constant Therapeutics LLC | Regulatory Tarix Orphan Receives FDA Fast Track Designation for TXA127 as Potential Treatment for Duchenne Muscular Dystrophy constanttherapeutics.com ↗ |
| 2015-08-03 | Constant Therapeutics LLC | Results Tarix Orphan, LLC Announces Positive Results with TXA127 in Animal Model of Congenital Muscular Dystrophy constanttherapeutics.com ↗
Researchers showed that two doses of TXA127, a pharmaceutical formulation of the natural Ang 1‐7 peptide, remarkably reduced inflammatory and fibrotic pathology, and also induced weight/muscle gain and increased muscle function. |
| 2015-07-13 | Constant Therapeutics LLC | Results Tarix Orphan, LLC Announces Positive Results with TXA127 in Animal Model of ALS constanttherapeutics.com ↗
The TXA127‐treated animals also exhibited a strong benefit in quality of life/disease progression scores for 128.33 days versus 102.67 days for control animals, as measured by the number of animals with scores ≤ 2 (animals ambulatory but dragging hind foot). |
| 2014-10-27 | Constant Therapeutics LLC | Results Tarix Orphan, LLC Announces Positive Results for TXA127 in Model of Limb Girdle Muscular Dystrophy constanttherapeutics.com ↗
The Tarix researchers showed that such mice treated daily for eight weeks with TXA127 via infusion by osmotic minipump exhibited a marked increase in activity compared to control animals. |
All press releases naming this drug 12 releases
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 38 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | talfirastide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06013839 ↗ |
| Known as | 5-ile-angiotensin-(1-7) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545347 ↗ |
| Known as | A(1-7) | “USB002 is pharmaceutically formulated Angiotensin 1-7 \[A(1-7)\], a non-hypertensive derivative of Angiotensin-II (A-II), and is suspended in a vehicle as a sterile solution of USB002.” NCT04778059 ↗1“TXA127 is pharmaceutically formulated Angiotensin 1-7 \[A(1-7)\]” NCT01554254 ↗ |
| Known as | Ang-(1-7) | “Angiotensin-(1-7) [Ang-(1-7)] is an endogenous peptide hormone of the renin-angiotensin system with antiproliferative and antiangiogenic properties.” PMID 19920106 ↗ Nov 20092“A substance, Angiotensin-(1-7) \[Ang-(1-7)\], is known to decrease inflammation in the brain.” NCT05336175 ↗ “Angiotensin 1-7 (Ang-(1-7))” NCT03252093 ↗ |
| Known as | Angiotensin 1-7 | “Single-arm safety/efficacy trial of TXA127 (Angiotensin 1-7) in subjects undergoing allogeneic peripheral blood stem cell transplantation for the treatment of a variety of...” NCT01882387 ↗27“USB002 is pharmaceutically formulated Angiotensin 1-7 \[A(1-7)\], a non-hypertensive derivative of Angiotensin-II (A-II), and is suspended in a vehicle as a sterile solution of USB002.” NCT04778059 ↗ “Single-arm safety/efficacy trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of hematologic malignancies.” NCT01882374 ↗ “Angiotensin-(1-7) is a peptide that is downregulated in COVID-19 patient and it may potentially improve respiratory function in this setting.” NCT04332666 ↗ “TXA127 is pharmaceutically-formulated angiotensin 1-7, a non-hypertensive derivative of angiotensin II” NCT01300611 ↗ “A substance, Angiotensin-(1-7) \[Ang-(1-7)\], is known to decrease inflammation in the brain.” NCT05336175 ↗ “Randomized Controlled Trial of Angiotensin 1-7 (TXA127) for the Treatment of Severe COVID-19” NCT04401423 ↗ “TXA127 is pharmaceutically formulated Angiotensin 1-7 \[A(1-7)\]” NCT01554254 ↗ “Angiotensin 1-7 (Ang-(1-7))” NCT03252093 ↗ |
| Known as | Angiotensin fragment 1-7 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545347 ↗ |
| Known as | Angiotensin peptide (1-7) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04375124 ↗ |
| Known as | Asp-arg-val-tyr-ile-his-pro | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545347 ↗ |
| Known as | Bf-angiotensin 1-7 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545347 ↗ |
| Known as | ETRX-101 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545347 ↗ |
| Known as | Human angiotensin ii (1-7) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545347 ↗ |
| Known as | Marstem | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545347 ↗ |
| Known as | Sh-heptapeptide-13 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545347 ↗ |
| Known as | Talfirastida | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545347 ↗ |
| Known as | TXA-127 | “2 investigational RAS agents, TXA-127 (synthetic angiotensin [1-7]) and TRV-027 (an angiotensin II type 1 receptor-biased ligand)” PMID 37039791 ↗ Apr 202312“A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1-7 (TXA-127) for the treatment of severe COVID-19.” PMID 35902867 ↗ Jul 2022 “talfirastide (TXA127)” NCT06135103 ↗ |
| Known as | USB-003 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545347 ↗ |
| Known as | USB002 | “USB002 is pharmaceutically formulated Angiotensin 1-7 \[A(1-7)\], a non-hypertensive derivative of Angiotensin-II (A-II), and is suspended in a vehicle as a sterile solution of USB002.” NCT04778059 ↗ |
| Action | Activate | “Proto-oncogene Mas agonist” CHEMBL3545347 ↗ |
| Action | Restore | “Angiotensin-(1-7) is a beneficial hormone that is reduced in obesity and restoration of this hormone improves endothelial function” NCT03604289 ↗ |
| Modality | Peptide | “Angiotensin-(1-7) [Ang-(1-7)] is an endogenous peptide hormone of the renin-angiotensin system with antiproliferative and antiangiogenic properties.” PMID 19920106 ↗ Nov 2009 |
| Route | Subcutaneous | “Patients receive therapeutic angiotensin-(1-7) subcutaneously on days 1-5.” NCT00471562 ↗ |
| Target | MAS1 | “Proto-oncogene Mas agonist” CHEMBL3545347 ↗ |